Around 3 Australians are diagnosed with chronic lymphocytic leukaemia - a blood cancer - every day. At HealthMatch, that makes our blood boil. Find a clinical trial for chronic lymphocytic leukaemia (CLL) today.
110,000 Australians are currently living with a blood cancer or disorder. The risk of an Australian being diagnosed with leukaemia before their 85th birthday is 1 in 55, and CLL is the most common type of leukaemia in Australia.
Leukaemia refers to cancers of the white or other blood-forming cells, which develop in the bone marrow. Chronic lymphocytic leukaemia - more commonly referred to as CLL - is a specific subtype of leukaemia that is slow-growing and affects 'B-lymphocytes', specialised types of white blood cells. Some patients with CLL may remain stable for months and years with little impact to their lifestyle and health, but for others the cancer cells may multiple uncontrollably.
Looking for how to help someone with chronic lymphocytic leukaemia? At HealthMatch, we’re bringing forward tomorrow’s treatments. We have multiple trials available for leukaemia, including ones aimed at stem cell transplants, new chemotherapies and biologic treatments.
Australians a day lose their lives to blood cancer ¹
of all diagnosed childhood cancers are leukaemia and lymphoma ²
Australians are diagnosed with blood cancer every year ³
The Leukaemia Foundation stands with Australians to help cure and conquer every blood cancer, with care. The Foundation was formed in 1975.
They fight to get people with blood cancer access to the best care; they accelerate research delivering rapid advancement in blood cancer diagnosis and treatment; they provide services and support to those affected by blood cancer.
Leukaemia Foundation Support Services
There are numerous services and resources available for Australians living with a blood cancer. These include practical and emotional support; accommodation and transport services; support groups, and more.
The resource pack from Lymphoma Australia aims to help increase patients' understanding through their lymphoma journey. Each pack contains a patient diary; a ‘what you need to know’ booklet; a living with lymphoma brochure and a nurse support line.
Leukaemia is the general name given to a group of cancers of white blood cells, or other blood-forming cells, that develop in the bone marrow.
It originates in blood cells that multiply in an uncontrolled way and don’t mature properly – these cells then don’t function as they should. This is referred to as a malignant change.
The disease is grouped in two ways: the type of blood cell affected, and how quickly the disease develops.
Myeloid and lymphocytic refers to the type of cells where the cancer first started: the myeloid stem cells or lymphoid stem cells.
Acute and chronic leukaemia refer to the speed in which the cancer develops: acute appears suddenly and grows quickly, whereas chronic appears gradually and develops slowly.
Common forms of acute leukaemia are acute myeloid leukaemia; acute lymphoblastic leukaemia and acute promyelocytic leukaemia.
Common forms of chronic leukaemia are chronic myeloid leukaemia; chronic lymphocytic leukaemia and hairy cell leukaemia.
People with chronic leukaemia may not experience symptoms early on. They may only develop symptoms after years of having the disease. Symptoms may include anaemia; a high temperature; night sweats; swollen glands; unintentional weight loss, and more.
Symptoms of acute leukaemia include tiredness; anaemia; repeated infections; recurrent nose bleeds; bone pain, and increased bruising and bleeding.
Common symptoms of lymphoma include unexplained fevers; swelling of the lymph glands; swelling of the abdomen; fatigue; generalised itching or rash, and more.
Leukaemia treatment is dictated by the type of leukaemia a person has. Acute leukaemias need to be treated typically within 24 hours of diagnosis.
For acute lymphoblastic leukaemia, treatment options include chemotherapy; peripheral blood stem cells transplantation; bone marrow transplantation; radiotherapy to the head and steroid therapy.
Treatment options for acute myeloid leukaemia include chemotherapy; peripheral blood stem cells transplantation, and radiotherapy to the head.
For chronic lymphoblastic leukaemia, treatment includes radiation therapy; chemotherapy; surgery, and monoclonal antibody therapy.
Chronic myeloid leukaemia can be treated with tyrosine kinase inhibitory therapy; chemotherapy; biologic therapy; high-dose chemotherapy with stem cell transplant; donor lymphocyte infusion and surgery.
The five-year survival rate for Hodgkin lymphoma is 87.5%. These days, most people treated for the disease can be cured. Many others who are treated remain disease-free, and well for a long time.
The five-year survival rate for non-Hodgkin lymphomas is 74.3%. B-cell non-Hodkin lymphomas have a higher chance of cure. For almost every type of non-Hodkin lymphoma, even if it cannot be cured, it can be controlled for many years.
The five-year survival rate for leukaemia is 61%. For most children and many adults who achieve remission (where the signs and symptoms of their cancer are reduced), the disease may be cured with peripheral blood stem cell or bone marrow transplantation, and chemotherapy.
A clinical trial is a scientific study involving patient or non-patient (healthy) human volunteers. They help determine whether medicines are safe and effective to introduce as new treatments for a particular disease or condition.
HealthMatch matches you to clinical trials, in an easy-to-understand process.
After completing a medical questionnaire, our platform searches for and filters eligible trials for you. You’re able to view matches and apply for trials, on your trial dashboard.
We’ll put you in direct contact with the trial group once you’ve been accepted. We won’t stop searching until we’ve found you the right match.
1 2 3 Leukaemia Foundation, Frequently Asked Questions